More from Newlink: Our lead HyperAcute™ immunotherapy product candidate, algenpantucel-L, is being studied under Fast Track and Orphan Drug designations in a phase 3 registration trial for patients with surgically-resected pancreatic cancer. Initiated in May 2010, enrollment of 722 patients across 70 centers was completed in September 2013.2,3 A second phase 3 trial of algenpantucel-L for locally advanced unresectable pancreatic cancer2,3 is currently enrolling patients.4 The second HyperAcute™ immunotherapy candidate in development, tergenpumatucel-L, is being compared to docetaxel in a randomized phase 2B/3 study of progressive or relapsed patients with non-small cell lung cancer.5 Additional HyperAcute™ immunotherapies are in development for various cancers, including melanoma, prostate cancer, and renal cancer.6,7 Unlike other immunotherapy products, HyperAcute™ immunotherapies are derived from allogeneic
(non-patient-specific) previously established cell lines,1,8 enabling a straightforward, efficient, and scalable manufacturing process.1
Our lead IDO pathway inhibitor, indoximod, is a novel immune checkpoint inhibitor that approaches cancer from a different direction, blocking tumor immunosuppression.1 An orally available small molecule,1,9,10 indoximod is being investigated as part of various combination regimens in metastatic breast cancer, and metastatic prostate cancer.11,12
News 
Market Data 
Discover 
